Company intelligence / Profile preview

OncoSpherix

Atlanta, Georgia, United Statesoncospherix.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Lead compounds have shown reduction in primary tumor growth, inhibition of metastases, and prolonged survival in mouse models of various cancers. The compounds are well-tolerated and can be combined with other therapeutics for enhanced cancer control.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

64B

Preclinical

Partnerships

Collaborations with other companies mentioned but specific partners not named

Beyond the preview

Go deeper on OncoSpherix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoSpherix.

Explore the full profile